Notice of Results
Investor Presentation via Investor Meet Company
LONDON and PHILADELPHIA - May 15, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, will announce its audited preliminary results for year ended December 31, 2024 ("FY24") on May 29, 2025.
Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 11:00 BST on the day.
The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor. Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until May 29 09:00 BST, or at any time during the live presentation.
The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.
-Ends-
For further information from Avacta, please contact:
| Avacta Group plc Michael Vinegrad, Group Communications Director | |
|
|
|
| Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
|
|
| Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers
| |
| ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor Contact Renee Leck THRUST Strategic Communications
|
|
| Media Contact Carly Scaduto Carly Scaduto Consulting |
|
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® Platform
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.